Benzinga | Dec 9, 2021 09:45PM EST

Oppenheimer Upgrades Sarepta Therapeutics to Outperform, Announces $125 Price Target

Oppenheimer analyst Hartaj Singh upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Perform to Outperform and announces $125 price target.